Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation? | Zendy

Tahmeed Contractor | Zendy; Atul Khasnis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?

Author(s) -

Tahmeed Contractor,

Atul Khasnis

Publication year - 2011

Publication title -

cardiology research and practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.437

H-Index - 35

eISSN - 2090-8016

pISSN - 2090-0597

DOI - 10.4061/2011/752808

Subject(s) - atrial fibrillation , medicine , warfarin , left atrial appendage occlusion , stroke (engine) , cardiology , percutaneous , population , atrial appendage , culprit , occlusion , intensive care medicine , myocardial infarction , mechanical engineering , environmental health , sinus rhythm , engineering

Atrial Fibrillation (AF) is a common arrhythmia with an incidence that is as high as 10% in the elderly population. Given the large proportion of strokes caused by AF as well as the associated morbidity and mortality, reducing stroke burden is the most important part of AF management. While warfarin significantly reduces the risk of AF-related stroke, perceived bleeding risks and compliance limit its widespread use in the high-risk AF population. The left atrial appendage is believed to be the “culprit” for thrombogenesis in nonvalvular AF and is a new therapeutic target for stroke prevention. The purpose of this review is to explore the evolving field of percutaneous LAA occlusion. After briefly highlighting the risk of stroke with AF, problems with warfarin, and the role of the LAA in clot formation, this article discusses the feasibility and efficacy of various devices which have been developed for percutaneous LAA occlusion

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research